Neximmune reports fourth quarter and full year 2021 financial results and provides business updates

Gaithersburg, md., march 09, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific t cells, today reported its fourth quarter and full year financial results for the full year 2021.
NEXI Ratings Summary
NEXI Quant Ranking